News HIV/AIDS

A single-tablet
regimen containing the hepatitis C virus (HCV) nucleotide polymerase
inhibitor sofosbuvir and
the NS5A inhibitor ledipasvir – the combination in Gilead Science’s
recently approved Harvoni pill – was well-tolerated and cured 97% of
patients with HCV genotype 1 in the Phase 3 ION trials, researchers
reported at the IDWeek 2014 meeting earlier this month in
Philadelphia.
The
advent of direct-acting antiviral agents has revolutionized treatment for
chronic hepatitis C, especially with the long-awaited

Low-level
elevations in important markers of systemic inflammation are associated with
the development of type-2 diabetes in people taking antiretroviral therapy
(ART), investigators report in the online edition of the Journal of Acquired Immune Defici…

57%
of people living with HIV in South Africa who are eligible to initiate antiretroviral
therapy (ART) are in care and only 37% of the 2012/2013 cohort of people
receiving ART were given a viral load test, according to new results announced
by the CEO…

«Siamo passati dal niente, al complicato, al semplice». Con queste poche ma chiare parole, Rosaria Iardino, presidente onorario di Network Persone Sieropositive (NPS) Italia Onlus, sintetizza l’evoluzione della terapia anti Hiv in 30 anni, da quando il virus fu scoperto e identificato.

The scale-up of
antiretroviral therapy (ART) programmes in Lusaka, Zambia, has been
accompanied by only modest reductions in the city’s mortality rates,
investigators report in the Bulletin of
the World Health Organization. A series of cross-sectional household
surveys conducted between 2004 and 2011 showed no significant reduction in the
mortality rate. The authors admit this finding

HIV continues to
be stigmatised despite increased access to antiretroviral therapy (ART),
according to research from Uganda published in the online edition of AIDS. Levels of internalised stigma
among people starting ART increased between 2007 and 2012…

People living with HIV in the United States who receive
their care through the Ryan White HIV/AIDS Program have good rates of retention
and virological suppression, investigators report in the online edition of Clinical
Infectious Diseases. Of the patients seen at least once in 2011, some 82%
were retained in care and 73% achieved virological

Liver cancer
screening for people with hepatitis B virus (HBV) infection should be
targeted at those with cirrhosis, according to the results of a systematic
review and meta-analysis published in PLOS
ONE. The risk of hepatocellular carcinoma (HCC) and…

A
study based on New York City that modelled pre-exposure prophylaxis (PrEP) uptake there has found that in
order to be affordable, PrEP would need to be tightly
targeted at gay men at higher risk of HIV infection. Within this target
population, it wou…

Sarà rimborsabile il Sovaldi, il nuovo e costosissimo farmaco per l‘Epatite C. L’Agenzia Italiana del Farmaco ha trovato l’accordo con la casa farmaceutica che lo produce, la Gilead Sciences. Il prezzo del Sofosbuvir (così si chiama il principio attivo), già calato da 58 mila a 37 mila euro per ciclo terapeutico, aveva scatenato le proteste delle associazioni dei malati.